| Literature DB >> 35650188 |
Mattia Marchi1,2, Laurent Elkrief3,4, Anne Alkema2, Willemijn van Gastel5, Chris D Schubart6, Kristel R van Eijk7, Jurjen J Luykx2, Susan Branje8, Stefanos Mastrotheodoros8,9, Gian M Galeazzi1,10, Jim van Os2, Charlotte A Cecil11,12, Patricia J Conrod3,4, Marco P Boks13.
Abstract
Childhood maltreatment (CM) and genetic vulnerability are both risk factors for psychosis, but the relations between them are not fully understood. Guided by the recent identification of genetic risk to CM, this study investigates the hypothesis that genetic risk to schizophrenia also increases the risk of CM and thus impacts psychosis risk. The relationship between schizophrenia polygenetic risk, CM, and psychotic-like experiences (PLE) was investigated in participants from the Utrecht Cannabis Cohort (N = 1262) and replicated in the independent IMAGEN cohort (N = 1740). Schizophrenia polygenic risk score (SZ-PRS) were calculated from the most recent GWAS. The relationship between CM, PRS, and PLE was first investigated using multivariate linear regression. Next, mediation of CM in the pathway linking SZ-PRS and PLE was examined by structural equation modeling, while adjusting for a set of potential mediators including cannabis use, smoking, and neuroticism. In agreement with previous studies, PLE were strongly associated with SZ-PRS (B = 0.190, p = 0.009) and CM (B = 0.575, p < 0.001). Novel was that CM was also significantly associated with SZ-PRS (B = 0.171, p = 0.001), and substantially mediated the effects of SZ-PRS on PLE (proportion mediated = 29.9%, p = 0.001). In the replication cohort, the analyses yielded similar results, confirming equally strong mediation by CM (proportion mediated = 34.7%, p = 0.009). Our results suggest that CM acts as a mediator in the causal pathway linking SZ-PRS and psychosis risk. These findings open new perspectives on the relations between genetic and environmental risks and warrant further studies into potential interventions to reduce psychosis risk in vulnerable people.Entities:
Mesh:
Year: 2022 PMID: 35650188 PMCID: PMC9160238 DOI: 10.1038/s41398-022-01975-1
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 7.989
Characteristics of the discovery sample and the replication sample.
| Variable | Discovery sample UCC ( | FMI | Replication sample IMAGEN ( | FMI |
|---|---|---|---|---|
| Male gender (%) | 606 (48%) | 813 (47%) | ||
| Age, mean (SD) in year | 20.5 (2.5) | 19.4 (1.5) | ||
| CTQ score, mean (SD) | 31.9 (8.4) | 0.23 | 40.2 (6.5) | 0.12 |
| Cannabis exposure ≥10 lifetime (%) | 404 (32%) | 0 | 361 (21%) | 0.063 |
| Tobacco daily consumption for at least 30 days in the last year (%) | 227 (30%) | 0.003 | 594 (34%) | 0.024 |
| CAPE-42 score, mean (SD) | 67.3 (13.9) | 0 | 60.6 (11.4) | 0 |
FMI fraction of missing information, SD standard deviation, CTQ Childhood Trauma Questionnaire, CAPE The Community Assessment of Psychic Experiences.
Results of parallel multiple mediator model in the discovery sample (UCC—above) and in the replication sample (IMAGEN cohort—below).
| Regressions | Unstandardized | Standardized estimate | |
|---|---|---|---|
| Direct effects | |||
| Outcome model: PLE ( | |||
| SZ-PRS | 0.190 (0.048; 0.331) | 0.071 | 0.009 |
| CM | 0.575 (0.480; 0.671) | 0.344 | <0.001 |
| Cannabis use | 2.71 (1.12; 4.30) | 0.091 | 0.001 |
| Mediator model: CM ( | |||
| SZ-PRS | 0.171 (0.072; 0.270) | 0.107 | 0.001 |
| Mediator model: cannabis use ( | |||
| SZ-PRS | 0.015 (0.010; 0.020) | 0.164 | <0.001 |
| Covariances | |||
| CM—cannabis use | 0.489 (0.248; 0.730) | 0.129 | <0.001 |
| Indirect effects (proportion mediated) | |||
| CM (29.9%) | 0.098 (0.039; 0.158) | 0.037 | 0.001 |
| Cannabis (12.2%) | 0.040 (0.013; 0.067) | 0.015 | 0.004 |
| Sum | 0.138 (0.073; 0.204) | 0.052 | <0.001 |
| Total effect | 0.328 (0.181; 0.474) | 0.123 | <0.001 |
| Direct effects | |||
| Outcome model: PLE ( | |||
| SZ-PRS | 0.489 (−0.145; 1.12) | 0.042 | 0.131 |
| CM | 0.496 (0.402; 0.589) | 0.316 | <0.001 |
| Cannabis use | 1.79 (0.302; 3.27) | 0.067 | 0.018 |
| Mediator model: CM ( | |||
| SZ-PRS | 0.603 (0.170; 1.04) | 0.082 | 0.006 |
| Mediator model: cannabis use ( | |||
| SZ-PRS | 0.041 (0.017; 0.065) | 0.095 | 0.001 |
| Covariances | |||
| CM—cannabis use | 0.389 (0.191; 0.588) | 0.123 | <0.001 |
| Indirect effects (proportion mediated) | |||
| CM (34.7%) | 0.299 (0.076; 0.522) | 0.026 | 0.009 |
| Cannabis (8.6%) | 0.074 (−0.001; 0.149) | 0.006 | 0.054 |
| Sum | 0.373 (0.135; 0.611) | 0.032 | 0.002 |
| Total effect | 0.862 (0.200; 1.52) | 0.075 | 0.011 |
95% CI 95% bias-corrected bootstrap confidence interval, UCC Utrecht Cannabis Cohort, PLE psychotic-like experiences, CM childhood maltreatment, SZ-PRS schizophrenia polygenic risk score at p value threshold 0.5.
Fig. 1Path diagram of parallel multiple mediator model in the discovery sample and in the replication sample.
Panel A UCC, above; Panel B IMAGEN cohort, below. The estimates reported are the unstandardized regression coefficients. *p < 0.05; **p < 0.01; ***p < 0.001. SZ-PRS schizophrenia polygenic risk score at p value threshold 0.5, CM childhood maltreatment, PLE psychotic-like experiences.
Results of parallel four-mediator model in the discovery sample (UCC).
| Regressions | Unstandardized | Standardized estimate | |
|---|---|---|---|
| Outcome model: PLE ( | |||
| SZ-PRS | 0.187 (0.035; 0.339) | 0.072 | 0.016 |
| CM | 0.223 (0.117; 0.328) | 0.143 | <0.001 |
| Cannabis use | 2.78 (0.538; 5.02) | 0.094 | 0.015 |
| Neuroticism | 0.302 (0.265; 0.338) | 0.541 | <0.001 |
| Nicotine | 2.57 (0.168; 4.61) | 0.082 | 0.035 |
| Mediator model: CM ( | |||
| SZ-PRS | 0.172 (0.036; 0.307) | 0.103 | 0.013 |
| Mediator model: cannabis use ( | |||
| SZ-PRS | 0.013 (0.006; 0.019) | 0.144 | <0.001 |
| Mediator model: neuroticism ( | |||
| SZ-PRS | 0.247 (−0.120; 0.614) | 0.053 | 0.186 |
| Mediator model: nicotine ( | |||
| SZ-PRS | 0.012 (0.006; 0.018) | 0.136 | <0.001 |
| CM—cannabis use | 0.389 (0.065; 0.713) | 0.101 | 0.018 |
| CM—neuroticism | 80.89 (62.81; 98.97) | 0.390 | <0.001 |
| CM—nicotine | 0.149 (−0.183; 0.481) | 0.038 | 0.379 |
| Cannabis—nicotine | 0.129 (0.112; 0.146) | 0.628 | <0.001 |
| Cannabis—neuroticism | 0.080 (−0.791; 0.951) | 0.007 | 0.858 |
| Neuroticism—nicotine | 0.472 (−0.423; 1.37) | 0.043 | 0.301 |
| CM (10.5%) | 0.038 (0.003; 0.073) | 0.015 | 0.033 |
| Cannabis (9.6%) | 0.035 (0.002; 0.068) | 0.013 | 0.038 |
| Neuroticism (20.7%) | 0.075 (−0.036; 0.186) | 0.029 | 0.188 |
| Nicotine (8.0%) | 0.029 (−0.002; 0.059) | 0.011 | 0.065 |
| Sum | 0.176 (0.045; 0.308) | 0.068 | 0.009 |
| 0.363 (0.181; 0.545) | 0.140 | <0.001 |
95% CI 95% bias-corrected bootstrap confidence interval, PLE psychotic-like experiences, CM childhood maltreatment, SZ-PRS schizophrenia polygenic risk score at p value threshold 0.5.
Fig. 2Path diagram of parallel four-mediator model in the discovery sample (UCC).
The estimates reported are the unstandardized regression coefficients. *p < 0.05; **p < 0.01; ***p < 0.001. SZ-PRS schizophrenia polygenic risk score at p value threshold 0.5, CM childhood maltreatment, PLE psychotic-like experiences.